JP2018512153A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512153A5 JP2018512153A5 JP2017553223A JP2017553223A JP2018512153A5 JP 2018512153 A5 JP2018512153 A5 JP 2018512153A5 JP 2017553223 A JP2017553223 A JP 2017553223A JP 2017553223 A JP2017553223 A JP 2017553223A JP 2018512153 A5 JP2018512153 A5 JP 2018512153A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- lymphoma
- seq
- bcma
- specific car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021122349A JP7301915B2 (ja) | 2015-04-13 | 2021-07-27 | Ｂ細胞成熟抗原を標的にするキメラ抗原受容体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562146825P | 2015-04-13 | 2015-04-13 | |
| US62/146,825 | 2015-04-13 | ||
| US201662286473P | 2016-01-25 | 2016-01-25 | |
| US62/286,473 | 2016-01-25 | ||
| US201662301177P | 2016-02-29 | 2016-02-29 | |
| US62/301,177 | 2016-02-29 | ||
| PCT/IB2016/051808 WO2016166630A1 (en) | 2015-04-13 | 2016-03-30 | Chimeric antigen receptors targeting b-cell maturation antigen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021122349A Division JP7301915B2 (ja) | 2015-04-13 | 2021-07-27 | Ｂ細胞成熟抗原を標的にするキメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512153A JP2018512153A (ja) | 2018-05-17 |
| JP2018512153A5 true JP2018512153A5 (enExample) | 2019-05-09 |
| JP6921001B2 JP6921001B2 (ja) | 2021-08-18 |
Family
ID=55650627
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553223A Active JP6921001B2 (ja) | 2015-04-13 | 2016-03-30 | Ｂ細胞成熟抗原を標的にするキメラ抗原受容体 |
| JP2021122349A Active JP7301915B2 (ja) | 2015-04-13 | 2021-07-27 | Ｂ細胞成熟抗原を標的にするキメラ抗原受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021122349A Active JP7301915B2 (ja) | 2015-04-13 | 2021-07-27 | Ｂ細胞成熟抗原を標的にするキメラ抗原受容体 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10294304B2 (enExample) |
| EP (2) | EP3757128B1 (enExample) |
| JP (2) | JP6921001B2 (enExample) |
| KR (3) | KR102208443B1 (enExample) |
| CN (2) | CN107980046B (enExample) |
| AU (3) | AU2016248947B2 (enExample) |
| CA (1) | CA2925589A1 (enExample) |
| CO (1) | CO2017010502A2 (enExample) |
| DK (1) | DK3283520T3 (enExample) |
| ES (2) | ES3039918T3 (enExample) |
| IL (2) | IL297223B2 (enExample) |
| MX (2) | MX377809B (enExample) |
| MY (1) | MY188432A (enExample) |
| PE (1) | PE20171653A1 (enExample) |
| PH (1) | PH12017501728A1 (enExample) |
| RU (1) | RU2706582C2 (enExample) |
| SG (2) | SG10201912666PA (enExample) |
| TW (2) | TWI700298B (enExample) |
| WO (1) | WO2016166630A1 (enExample) |
| ZA (1) | ZA201706384B (enExample) |
Families Citing this family (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201806573TA (en) * | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| EP3131927B8 (en) | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| EP3250602A1 (en) | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| HUE057285T2 (hu) | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| TWI700298B (zh) | 2015-04-13 | 2020-08-01 | 美商輝瑞股份有限公司 | 靶向ｂ細胞成熟抗原之嵌合型抗原受體類 |
| SG10201912519VA (en) | 2016-04-01 | 2020-02-27 | Kite Pharma Inc | Chimeric receptors and methods of use thereof |
| KR102427334B1 (ko) | 2016-04-01 | 2022-08-03 | 카이트 파마 인코포레이티드 | 키메라 항원 및 t 세포 수용체 및 사용 방법 |
| NZ746700A (en) | 2016-04-01 | 2023-04-28 | Kite Pharma Inc | Bcma binding molecules and methods of use thereof |
| IL308831A (en) | 2016-04-08 | 2024-01-01 | Immunocore Ltd | T cell receptors |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2018064602A1 (en) * | 2016-09-30 | 2018-04-05 | Baylor College Of Medicine | Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| EP3554544A4 (en) | 2016-12-16 | 2020-07-29 | Bluefin Biomedicine, Inc. | ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| PE20241587A1 (es) * | 2017-06-02 | 2024-08-01 | Pfizer | Receptores de antigenos quimericos que se dirigen a flt3 |
| JP7234142B2 (ja) | 2017-06-02 | 2023-03-07 | ファイザー・インク | Ｆｌｔ３に特異的な抗体およびその使用 |
| SG11202003415XA (en) | 2017-10-18 | 2020-05-28 | Novartis Ag | Compositions and methods for selective protein degradation |
| US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| US11066475B2 (en) | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
| AU2018359907A1 (en) | 2017-11-06 | 2020-05-07 | Fred Hutchinson Cancer Center | Combination of a cell therapy and a gamma secretase inhibitor |
| WO2019099639A1 (en) | 2017-11-15 | 2019-05-23 | Navartis Ag | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies |
| MX2020005651A (es) | 2017-11-30 | 2020-10-28 | Novartis Ag | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. |
| CN119193493A (zh) | 2017-12-08 | 2024-12-27 | 朱诺治疗学股份有限公司 | 生产工程化t细胞组合物的过程 |
| CN109971715A (zh) * | 2017-12-28 | 2019-07-05 | 深圳华大生命科学研究院 | 一种扩增特异性car-t细胞的培养方法 |
| WO2019136432A1 (en) | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
| AU2019215031C1 (en) | 2018-01-31 | 2026-02-26 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| CN110662771B (zh) * | 2018-02-01 | 2023-07-28 | 南京驯鹿生物技术股份有限公司 | 一种结合bcma的嵌合抗原受体(car)及其应用 |
| ES2968880T3 (es) * | 2018-02-01 | 2024-05-14 | Nanjing Iaso Biotechnology Co Ltd | Receptor de antígeno quimérico (CAR) que se une a BCMA, y usos del mismo |
| MX2020008184A (es) * | 2018-02-01 | 2020-09-22 | Pfizer | Receptores de antigeno quimericos dirigidos a cd70. |
| MX2020008183A (es) | 2018-02-01 | 2020-09-22 | Pfizer | Anticuerpos especificos para cd70 y sus usos. |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| BR112020017053A2 (pt) * | 2018-02-21 | 2020-12-15 | Celgene Corporation | Anticorpos que se ligam ao bcma e usos dos mesmos |
| CN112136048A (zh) | 2018-02-21 | 2020-12-25 | 艾迪菲斯健康有限公司 | 测量全身性慢性炎性衰老的方法 |
| AU2019227979B2 (en) | 2018-03-02 | 2024-09-05 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| IT201800003464A1 (it) | 2018-03-13 | 2019-09-13 | Ospedale Pediatrico Bambino Gesu | Cellule T CAR-CD30 per il trattamento di tumori CD30+ |
| CN116836297A (zh) | 2018-04-12 | 2023-10-03 | 上海赛比曼生物科技有限公司 | 靶向bcma的嵌合抗原受体及其制法和应用 |
| PE20210320A1 (es) | 2018-06-01 | 2021-02-16 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas |
| IL279367B2 (en) | 2018-06-13 | 2026-05-01 | Novartis Ag | BCMA chimeric antigen receptors and their uses |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| LT4324851T (lt) | 2018-07-19 | 2025-10-10 | Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas | |
| CN112930199B (zh) * | 2018-07-24 | 2024-08-13 | 恺兴生命科技(上海)有限公司 | 免疫效应细胞治疗肿瘤的方法 |
| CN110850067B (zh) * | 2018-08-21 | 2023-08-15 | 上海恒润达生生物科技股份有限公司 | 嵌合抗原受体亲和力检测方法 |
| SI3844267T1 (sl) | 2018-08-31 | 2025-10-30 | Novartis Ag | Postopki izdelave celic, ki izražajo receptorje himernega antigena |
| US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
| SG11202102781UA (en) | 2018-09-27 | 2021-04-29 | Autolus Ltd | Chimeric antigen receptor |
| US12473345B2 (en) | 2018-11-01 | 2025-11-18 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| CN119569895A (zh) | 2018-11-01 | 2025-03-07 | 朱诺治疗学股份有限公司 | G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体 |
| PE20211915A1 (es) * | 2018-12-01 | 2021-09-28 | Allogene Therapeutics Inc | Receptores de antigenos quimericos dirigidos al antigeno de maduracion de celulas b y sus metodos de uso |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| US20220152150A1 (en) | 2019-02-25 | 2022-05-19 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| IL328846A (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases |
| IL285941B1 (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN |
| EP3942025A1 (en) | 2019-03-21 | 2022-01-26 | Novartis AG | Car-t cell therapies with enhanced efficacy |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
| WO2020232243A2 (en) * | 2019-05-14 | 2020-11-19 | Froude Jeffrey W | Antibodies to sudan and ebola virus |
| US20200370013A1 (en) * | 2019-05-20 | 2020-11-26 | The Trustees Of The University Of Pennsylvania | Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors |
| AU2020279224B2 (en) | 2019-05-21 | 2024-12-05 | Novartis Ag | Trispecific binding molecules against BCMA and uses thereof |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| CA3140102A1 (en) * | 2019-05-30 | 2020-12-03 | Dina SCHNEIDER | Compositions and methods for treating cancer with anti-bcma immunotherapy |
| SE544015C2 (en) * | 2019-06-18 | 2021-11-02 | Tx Medic Ab | Allogenic car-t cell therapy |
| WO2021026362A1 (en) | 2019-08-07 | 2021-02-11 | Edifice Health, Inc. | Treatment of prevention of cardiovascular disease |
| AU2020334317A1 (en) | 2019-08-16 | 2022-04-07 | Janssen Biotech, Inc. | Therapeutic immune cells with improved function and methods for making the same |
| BR112022003553A2 (pt) | 2019-08-30 | 2022-05-24 | Allogene Therapeutics Inc | Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta |
| JP2022548902A (ja) * | 2019-09-18 | 2022-11-22 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｂｃｍａ陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法 |
| JP2023501871A (ja) * | 2019-09-20 | 2023-01-20 | 上海吉倍生物技術有限公司 | Ｂｃｍａ標的化抗体及びキメラ抗原受容体 |
| AU2020358898B2 (en) * | 2019-10-01 | 2025-10-16 | Epsilogen Ltd | Hybrid antibody |
| WO2021090062A1 (en) * | 2019-11-07 | 2021-05-14 | Eisai R&D Management Co., Ltd. | Anti-mesothelin eribulin antibody-drug conjugates and methods of use |
| WO2021108661A2 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
| WO2021113776A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods |
| US20230112444A1 (en) * | 2020-01-16 | 2023-04-13 | Springworks Therapeutics, Inc. | Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma secretase inhibitors |
| PE20221757A1 (es) | 2020-02-24 | 2022-11-11 | Allogene Therapeutics Inc | Celulas t con car de bcma con actividades mejoradas |
| JP2023516008A (ja) | 2020-02-27 | 2023-04-17 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
| IL295878A (en) | 2020-02-27 | 2022-10-01 | Novartis Ag | Methods for producing cells expressing a chimeric antigen receptor |
| GB202005216D0 (en) * | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| US20210315921A1 (en) * | 2020-04-13 | 2021-10-14 | Edifice Health, Inc. | Compounds and Methods for Modifying iAge |
| GB202007842D0 (en) * | 2020-05-26 | 2020-07-08 | Quell Therapeutics Ltd | Polypeptide useful in adoptive cell therapy |
| US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| KR102316091B1 (ko) * | 2020-06-17 | 2021-10-25 | 국립암센터 | Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도 |
| WO2022037527A1 (zh) * | 2020-08-20 | 2022-02-24 | 正大天晴药业集团股份有限公司 | 结合bcma的单可变结构域及抗原结合分子 |
| WO2022040586A2 (en) | 2020-08-21 | 2022-02-24 | Novartis Ag | Compositions and methods for in vivo generation of car expressing cells |
| CN114106176B (zh) * | 2020-09-01 | 2024-04-09 | 深圳市菲鹏生物治疗股份有限公司 | Cd22抗体及其应用 |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| JP2024500189A (ja) | 2020-12-21 | 2024-01-04 | アロジーン セラピューティクス，インコーポレイテッド | プロテアーゼ活性化ｃｄ４５ゲートｃａｒ |
| USD939199S1 (en) | 2021-01-29 | 2021-12-28 | O2 Partners, Llc | Shoe insole |
| MX2023008809A (es) | 2021-01-29 | 2023-08-04 | Allogene Therapeutics Inc | ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS. |
| AR125468A1 (es) | 2021-04-27 | 2023-07-19 | Novartis Ag | Sistema de producción de vectores virales |
| EP4388000A1 (en) | 2021-08-20 | 2024-06-26 | Novartis AG | Methods of making chimeric antigen receptor?expressing cells |
| MX2024002590A (es) | 2021-09-01 | 2024-03-22 | Springworks Therapeutics Inc | Sintesis de nirogacestat. |
| US20230407252A1 (en) | 2022-04-28 | 2023-12-21 | Allogene Therapeutics, Inc. | Methods for donor cell analysis |
| EP4565262A2 (en) | 2022-08-05 | 2025-06-11 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
| CN119836438A (zh) * | 2022-09-19 | 2025-04-15 | 艾洛基治疗公司 | B-细胞成熟抗原（bcma）抗独特型抗体 |
| JP2026519263A (ja) | 2022-10-26 | 2026-06-15 | ノバルティス アーゲー | レンチウイルス製剤 |
| TW202440636A (zh) | 2023-03-21 | 2024-10-16 | 美商傳記５５有限公司 | Ｃｄ１９／ｃｄ３８多特異性抗體 |
| PE20260290A1 (es) | 2023-03-31 | 2026-02-10 | Abelzeta Inc | Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025160340A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| TW202617750A (zh) * | 2024-07-10 | 2026-05-01 | 美商安吉利斯治療學公司 | 包含表位與多肽的組成物及方法 |
| WO2026151982A1 (en) | 2025-01-10 | 2026-07-16 | Regeneron Pharmaceuticals, Inc. | Methods of treating food allergy by administering an il-4r antagonist and a bcma targeting agent |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| HK1043608B (en) | 1999-08-17 | 2007-12-07 | Biogen Ma Inc. | Baff receptor (bcma), an immunoregulatory agent |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| AU2002238052A1 (en) * | 2001-02-20 | 2002-09-04 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| AU2003221256A1 (en) | 2002-02-21 | 2003-09-09 | Biogen Idec Ma Inc. | Use of bcma as an immunoregulatory agent |
| PL2132230T3 (pl) * | 2007-03-22 | 2014-09-30 | Genentech Inc | Apoptotyczne przeciwciała anty-IgE wiążące IgE związaną z błoną |
| CN102421801B (zh) | 2009-03-10 | 2016-03-16 | 比奥根Ma公司 | 抗-bcma抗体 |
| US20120189618A1 (en) | 2010-07-16 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Superior efficacy of cd37 antibodies in cll blood samples |
| SG189482A1 (en) | 2010-10-27 | 2013-05-31 | Cellectis | Method for increasing the efficiency of double-strand break-induced mutagenesis |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| EP2714737A1 (en) * | 2011-05-27 | 2014-04-09 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| AU2013246443B2 (en) * | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| IN2014MN02293A (enExample) | 2012-04-20 | 2015-08-07 | Emergent Product Dev Seattle | |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| AU2013312838B2 (en) | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| EP2914628A1 (en) * | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| KR102391731B1 (ko) | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP2970372B1 (en) * | 2013-03-15 | 2020-09-30 | Celgene Corporation | Modified t lymphocytes |
| AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| WO2014172584A1 (en) * | 2013-04-17 | 2014-10-23 | Baylor College Of Medicine | IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER |
| CA2912375C (en) | 2013-05-13 | 2023-03-14 | Cellectis | Methods for engineering highly active t cell for immunotherapy |
| SI2997141T1 (sl) | 2013-05-13 | 2023-04-28 | Cellectis | CD19 specifični himerni antigenski receptor in njegova uporaba |
| JP6608807B2 (ja) | 2013-05-29 | 2019-11-20 | セレクティス | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 |
| GB201317928D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| EP3243831A1 (en) | 2014-02-27 | 2017-11-15 | Ucl Business Plc | Variants of the proliferation-inducing ligand (april) |
| EP3131927B8 (en) * | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| BR112016024546A2 (pt) | 2014-04-30 | 2018-01-23 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| EP3172231B1 (en) | 2014-07-24 | 2021-05-05 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
| CN113698497A (zh) | 2014-12-05 | 2021-11-26 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的嵌合抗原受体及其用途 |
| US10383929B2 (en) | 2014-12-12 | 2019-08-20 | Bluebird Bio, Inc. | BCMA chimeric antigen receptors |
| EP3250602A1 (en) | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| TWI700298B (zh) | 2015-04-13 | 2020-08-01 | 美商輝瑞股份有限公司 | 靶向ｂ細胞成熟抗原之嵌合型抗原受體類 |
| HUE057285T2 (hu) * | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| PE20211915A1 (es) * | 2018-12-01 | 2021-09-28 | Allogene Therapeutics Inc | Receptores de antigenos quimericos dirigidos al antigeno de maduracion de celulas b y sus metodos de uso |
-
2016
- 2016-03-30 TW TW107117083A patent/TWI700298B/zh active
- 2016-03-30 RU RU2017133952A patent/RU2706582C2/ru active
- 2016-03-30 JP JP2017553223A patent/JP6921001B2/ja active Active
- 2016-03-30 ES ES20172811T patent/ES3039918T3/es active Active
- 2016-03-30 PE PE2017001979A patent/PE20171653A1/es unknown
- 2016-03-30 WO PCT/IB2016/051808 patent/WO2016166630A1/en not_active Ceased
- 2016-03-30 DK DK16714020.1T patent/DK3283520T3/da active
- 2016-03-30 ES ES16714020T patent/ES2807591T3/es active Active
- 2016-03-30 EP EP20172811.0A patent/EP3757128B1/en active Active
- 2016-03-30 KR KR1020177032318A patent/KR102208443B1/ko active Active
- 2016-03-30 KR KR1020227000405A patent/KR102528825B1/ko active Active
- 2016-03-30 EP EP16714020.1A patent/EP3283520B1/en active Active
- 2016-03-30 MX MX2017013298A patent/MX377809B/es unknown
- 2016-03-30 KR KR1020217002139A patent/KR102349475B1/ko active Active
- 2016-03-30 AU AU2016248947A patent/AU2016248947B2/en active Active
- 2016-03-30 CN CN201680021803.2A patent/CN107980046B/zh active Active
- 2016-03-30 TW TW105110156A patent/TWI631138B/zh active
- 2016-03-30 MY MYPI2017703826A patent/MY188432A/en unknown
- 2016-03-30 IL IL297223A patent/IL297223B2/en unknown
- 2016-03-30 SG SG10201912666PA patent/SG10201912666PA/en unknown
- 2016-03-30 CN CN202111463749.6A patent/CN114149511A/zh active Pending
- 2016-03-30 SG SG11201707089WA patent/SG11201707089WA/en unknown
- 2016-03-30 US US15/085,317 patent/US10294304B2/en active Active
- 2016-03-30 CA CA2925589A patent/CA2925589A1/en active Pending
-
2017
- 2017-09-03 IL IL254276A patent/IL254276B2/en unknown
- 2017-09-20 PH PH12017501728A patent/PH12017501728A1/en unknown
- 2017-09-21 ZA ZA2017/06384A patent/ZA201706384B/en unknown
- 2017-10-13 MX MX2020012573A patent/MX2020012573A/es unknown
- 2017-10-13 CO CONC2017/0010502A patent/CO2017010502A2/es unknown
-
2019
- 2019-04-15 US US16/384,719 patent/US11312782B2/en active Active
-
2020
- 2020-10-14 AU AU2020256365A patent/AU2020256365B2/en active Active
-
2021
- 2021-07-27 JP JP2021122349A patent/JP7301915B2/ja active Active
-
2022
- 2022-03-15 US US17/695,769 patent/US11912776B2/en active Active
-
2023
- 2023-08-24 AU AU2023219928A patent/AU2023219928A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7212222B2 (ja) | Ｃｄ１９及びｃｄ２０を標的とする組み合わされたキメラ抗原受容体並びにその適用 | |
| TWI883026B (zh) | 抗ｄｌｌ３嵌合抗原受體及其用途 | |
| CA2784814C (en) | Heterodimer binding proteins and uses thereof | |
| RU2017133952A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания B-клеток | |
| JP2021518108A5 (enExample) | ||
| CN110325209A (zh) | 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途 | |
| JP2016513467A5 (enExample) | ||
| KR20230100748A (ko) | 키메라 항원 수용체 및 pd-1 억제제의 조합 요법 | |
| CN113614109A (zh) | 双功能抗pd-1/il-7分子 | |
| JP2015527070A5 (enExample) | ||
| JP2016514462A5 (enExample) | ||
| EP3774921A1 (en) | Antibody variable domains targeting dll3, and use thereof | |
| JP2017522893A5 (enExample) | ||
| US20220411512A1 (en) | Combination treatment for cancer | |
| JP2023524997A (ja) | Ｃｌｅｃ１２ａを標的とする抗体及びその使用 | |
| WO2021223720A1 (zh) | 人源化cd19抗体及其应用 | |
| CN114585416A (zh) | 用于调节免疫应答和治疗疾病的btla结合（cd272）抗体 | |
| CN114790241B (zh) | 抗tigit抗体及其应用 | |
| CA3070290A1 (en) | Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody | |
| TW202313682A (zh) | 抗icos抗體之用途 | |
| WO2024173376A2 (en) | Combination therapy comprising multispecific gamma delta tcr antibodies | |
| WO2025029484A1 (en) | Methods of blood cell-mediated in vivo car cell expansion and engraftment | |
| TW202426503A (zh) | 癌症治療中與ｐｄ－１訊息抑制劑組合之抗ｃｌｄｎ４－抗ｃｄ１３７雙特異性抗體的用途 | |
| WO2023199927A1 (ja) | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体の使用 | |
| TW202544034A (zh) | 結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體 |